Opinion|Videos|April 29, 2024
Rentschler Biopharma: A 50-year Legacy of Exceptional CDMO Expertise
Author(s)Rentschler Biopharma
Explore how Rentschler Biopharma duels biopharmaceutical innovation, spanning from pioneering biological products to cutting-edge cell and gene therapies
Benedikt von Braunmühl (CEO) and Federico Pollano (vice president of business development) at Rentschler Biopharma explain what sets their CDMO apart. Viewers will learn about:
- What exceptional CDMO expertise means: 25% of all FDA approved biopharmaceuticals in 2023 were supported by the company
- Rentschler Biopharma’s US offerings, as well as commercial and development expertise
- How the company is leveraging its expertise in the field of gene therapy
Related Content
Trending on Pharmaceutical Technology
1
Roche Gets Priority Review for Enspryng; Announces Sequencing Platform
2
FDA Grants First-in-Class Approval for Treg Cell Therapy in Blood Cancer Transplant Patients
3
Manufacturing Deficiencies Behind FDA's Oxylanthanum Carbonate Rejection
4
Regulatory Developments Impacting Biologics
5